<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01873053</url>
  </required_header>
  <id_info>
    <org_study_id>KR-KHNMC-OA02</org_study_id>
    <nct_id>NCT01873053</nct_id>
  </id_info>
  <brief_title>A 12 Week, Phase II Trial to Evaluate the Efficacy and Safety of WIN-34B in Patients With Osteoarthritis of the Knee</brief_title>
  <official_title>A 12 Week, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of WIN-34B in Patients With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kyung Hee University Hospital at Gangdong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hamsoa Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyunghee University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a multi-center, randomized, double-blind, placebo-controlled, parallel, phase
      II clinical trial and aimed at osteoarthritis of the knee.

      Patients who signed informed consent voluntarily and eligible for this study are assigned
      randomly to one of 3 groups after 2 week-Washout period.

        1. st group (experimental) : WIN-34B 450mg BID

        2. nd group (experimental) : WIN-34B 900mg BID

        3. rd group (Comparator) : Placebo BID

      Patients will take WIN-34B or Placebo BID for 12 weeks. Based on baseline, after 4
      weeks(Visit 3) and 12 weeks(Visit 5), Researchers check patients' physical examination,
      questionnaire, laboratory experiment.

      After 8 weeks(Visit 4), researchers check adverse effects and current medication status via
      telephone interview.

      After 12 weeks(Visit 5) patients stop taking drugs and after 16 weeks(Visit 6) researchers
      check patients' physical examination, questionnaire, adverse effects and current medication
      status.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>KWOMAC(Korean Western Ontario and McMaster Universities Osteoarthritis Index)</measure>
    <time_frame>Changes from baseline at 4, 12, 16weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain VAS 100mm</measure>
    <time_frame>Visit1(screening), Visit2(0week), Visit3(4weeks), Visit4(8weeks), Visit5(12weeks), Visit6(16weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KHAQ(Korean Health Assessment Questionnaire)</measure>
    <time_frame>Visit2(0week), Visit3(4weeks), Visit5(12weeks), Visit6(16weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LFI(Lequesne's Functional Index)</measure>
    <time_frame>Visit2(0week), Visit3(4weeks), Visit5(12weeks), Visit6(16weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nine Point Scale</measure>
    <time_frame>Visit5(12weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cold-Heat Questionnaire</measure>
    <time_frame>Visit2(0week), Visit3(4weeks), Visit5(12weeks), Visit6(16weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose and Frequency of Rescue drug</measure>
    <time_frame>Visit2(0week), Visit3(4weeks), Visit4(8weeks), Visit5(12weeks), Visit6(16weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety(Vital sign, Physical examination, Laboratory experiment, ECG, Adverse event)</measure>
    <time_frame>Visit1(screening), Visit2(0week), Visit3(4weeks), Visit4(8weeks), Visit5(12weeks), Visit6(16weeks) - There are some differences in subgroup at every visit</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>1st group : WIN-34B 900mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to 1st group take WIN-34B 450mg BID for 12weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2nd group : WIN-34B 1800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to 2nd group take WIN-34B 900mg BID for 12weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3rd group : Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients assigned to 3rd group take Placebo BID for 12weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WIN-34B</intervention_name>
    <description>Patients assigned to Experimental group(1st or 2nd group) take WIN-34B 450mg or WIN-34B 900mg BID for 12weeks</description>
    <arm_group_label>1st group : WIN-34B 900mg</arm_group_label>
    <arm_group_label>2nd group : WIN-34B 1800mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>3rd group : Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Being between 35 and 80 years of age

          2. Diagnosed with Osteoarthritis of the knee at least 3 months

          3. Diagnosed with Osteoarthritis of the knee, based on ACR criteria

          4. Able to communicate with researchers and write questionnaires

          5. At the screening visit, checking 100mm Pain VAS at least 80mm

          6. At randomization(Visit 2), checking 100mm Pain VAS over 50mm

          7. Agreeing to participate and signing informed consent voluntarily

        Exclusion Criteria:

          1. Previous intra-articular injection on knee within 3 months

          2. Previous knee surgery within 6 months or scheduled procedures

          3. Other diseases that could affect or interfere with the therapeutic outcomes

          4. Experiencing habitual use of psychotropic, narcotic analgesic drugs over 1 week

          5. Diagnosed with gastrointestinal diseases, unable to stop medicines during the study

          6. At the screening visit, identified liver dysfunction

          7. At the screening visit, identified renal dysfunction

          8. Patients who cannot take NSAIDs

          9. Pregnancy and breast-feeding (women of childbearing age need pregnancy test)

         10. Physicological or mental disorders, including drug-takers

         11. Orthopedic diseases that could affect or interfere with the therapeutic outcomes

         12. Inappropriate for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong-Suk Park</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyung Hee University Hospital at Gangdong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyung Hee University Oriental Medicine Hospital at Gangdong</name>
      <address>
        <city>Seoul</city>
        <zip>134-727</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2013</study_first_submitted>
  <study_first_submitted_qc>June 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2013</study_first_posted>
  <last_update_submitted>November 20, 2015</last_update_submitted>
  <last_update_submitted_qc>November 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyunghee University Medical Center</investigator_affiliation>
    <investigator_full_name>Park Dong-Suk</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Osteoarthritis, Knee</keyword>
  <keyword>WIN-34B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

